Insights On CONTRACT PHARMA MANUFACTURING

  1. Late‑Stage Progress In Excipients For Precision Nanomedicine 5/6/2026

    View late‑stage development and GMP manufacturing of novel excipients for nanomedicines, emphasizing regulatory rigor, process optimization, analytics, and scale‑up for lipid‑based delivery systems.

  2. Nucleic Acid-LNP Ultrafiltration And Diafiltration 5/5/2026

    Downstream filtration can make or break LNPs at scale. See how membrane format, loading, and shear affect recovery and stability — and how alternative TFF lowers scale‑up risk.

  3. Spray Dried Biologics For Nasal Dosage Forms 5/5/2026

    A fireside chat explores spray drying for nasal biologics, covering formulation science, particle design, delivery advantages, and testing strategies to move from concept to clinic.

  4. Spray Dried Biologics For OSD Dosage Forms 5/5/2026

    A fireside chat explores spray drying basics, oral biologic dosage forms, formulation hurdles, and testing strategies to ensure drug product quality, safety, and performance.

  5. Why Comprehensive Analytical Services Are Core To The Future Of Antibody-Drug Conjugates 5/5/2026

    ADCs require integrated, early-stage analytics to manage complex interactions among components, enabling better characterization, reduced development risk, and faster, more reliable progression from discovery through regulatory approval.

  6. Advancing Cell Culture Strategies To Accelerate Biologics Development 5/5/2026

    Integrated stable expression strategies accelerate biologics material generation, improving scalability, consistency, and early developability insights while reducing bottlenecks, variability, and risks in transitioning from discovery to manufacturing.

  7. Successful Tech Transfer Meets Commercial Needs 5/5/2026

    An accelerated technology transfer reduced time to PPQ by over 25%, overcoming novel raw materials, unique IP constraints, and late‑stage process optimization to meet urgent commercial demand.

  8. Solving The DNA Knock-In Problem 5/1/2026

    An in‑depth exploration of why large, precise DNA knock‑ins limit cell therapy progress—and how site‑specific integration enables durable, scalable genetic engineering solutions.

  9. Expanding The Capabilities Of Targeted Integration 5/1/2026

    See the demonstration of precise, site‑specific integration of a 50 kb multi‑gene construct into human iPSCs, overcoming size limits of traditional genome‑engineering approaches.

  10. Bispecific T- Cell Engager (BiTE) Screening, Automated Pipeline 5/1/2026

    View automated, high‑throughput BiTE screening in mammalian cells, enabling rapid discovery of efficacious variants through precise genomic integration and scalable workflows.